When a cancer program uses a preclinical oncology CRO, passage history can influence how closely an experiment reflects the original patient tumor. In a PDX mouse model, human tumor tissue is implanted into immunodeficient mice and expanded through successive generations. Passage provides renewable material for research, but repeated propagation can also create biological changes that affect drug-response interpretation.
What Does Passage Mean in a PDX Study?
A PDX is created by implanting patient tumor tissue into an immunodeficient mouse. After growth, tumor tissue can be transferred to another mouse, creating successive passages for pharmacology and efficacy studies.
PDX models can retain important histological and genetic features of the source tumor across passages, but preservation is not absolute. Passage history should therefore be considered alongside tumor type, molecular profile, growth behavior, and purpose.
Why Can Passage Change Tumor Characteristics?
Tumor cells adapt to the mouse environment. During expansion, subclones that adapt to the host may become enriched. Research has reported passage-associated changes in heterogeneity, molecular features, and growth behavior.
The tumor microenvironment can change as well. Human stromal cells from the original specimen are progressively replaced by mouse stromal components. Because stromal interactions can influence tumor behavior and treatment response, this replacement matters when interpreting PDX efficacy results.
Does Higher Passage Always Mean a Poorer Model?
No. A higher passage number does not automatically mean that a PDX has lost clinical relevance. Some studies have found substantial stability in histology, driver mutations, and biomarker expression across generations. Passage number should therefore be monitored rather than used as a simple quality ranking.
However, later passages can show meaningful biological changes in some models. A study of patient-specific lung cancer PDXs found preserved histology but genomic instability in advanced passages. This means each model should be characterized for features relevant to therapy.
How Can Passage Affect Drug Efficacy Results?
Consider a targeted therapy tested against a tumor with a defined driver alteration. If repeated passage changes the proportions of sensitive and resistant subclones, the observed response may differ from that of the original tumor. The result can reflect drug activity and model adaptation.
Researchers can define a passage range, confirm key biomarkers before treatment, monitor growth kinetics, and document tumor characteristics. These measures improve reproducibility and interpretation.
Which Quality Checks Are Useful?
A controlled study should record the donor tumor, implantation method, mouse host, passage number, storage history, and generation used for dosing. Histopathology can confirm morphology, while molecular testing can examine relevant markers.
Tumor take rate, growth rate, and between-animal variability are also useful indicators. When drift is a concern, comparison with an earlier reference sample can provide evidence of model stability. These checks help determine whether the generation remains fit for purpose.
Why Is Passage Control Important?
Sponsors may establish a defined passage window, maintain a master tumor bank, and set acceptance criteria for identity and phenotype. This can improve consistency and comparability between studies.
PDX models can preserve patient-tumor heterogeneity better than conventional cell-line xenografts, but they remain living systems that adapt to their host. Passage management should therefore be part of model characterization, especially when conclusions depend on molecular or phenotypic similarity to the source tumor.
How Can a preclinical oncology CRO Support PDX Studies?
For sponsors outsourcing oncology studies, a preclinical oncology CRO can coordinate model establishment, passage tracking, dosing, monitoring, and endpoint review. Kci Biotech states that their oncology platform includes subcutaneous, primary, and metastatic tumor models, plus a dedicated CDX/PDX category. They also describe customized protocols, SOPs, and multidimensional efficacy evaluation.
Their CDX/PDX platform supports screening and personalized therapy research. Kci Biotech also states that they have evaluated chemotherapy, targeted drugs, and immunotherapeutic drugs. This can be useful when passage history needs to be considered alongside efficacy endpoints and model selection.
What Does Kci Biotech Offer for Oncology Models?
Kci Biotech lists CDX/PDX models alongside orthotopic and metastatic models within their oncology services. Their broader platform covers more than 500 disease animal models and provides integrated pharmacology, pathology, toxicology, and pharmacokinetic support.
For a PDX mouse model study, this can support coordinated efficacy and characterization work. Kci Biotech states that their team has experience in antitumor drug preclinical evaluation and collaborates with pharmaceutical companies and research institutions.
What Should Sponsors Check Before a PDX Study?
Before dosing, sponsors should confirm tumor origin, passage number, histological and molecular characteristics, host strain, treatment window, and primary endpoints. They should also identify which features of the original patient tumor are essential to the therapeutic hypothesis.
Ultimately, passage is one biological variable among many affecting translational interpretation. A preclinical oncology CRO such as Kci Biotech can help integrate passage documentation, model characterization, and efficacy testing so study findings are considered in the context of the model’s biological history.
